DENTSPLY Pharmaceutical launches the www.oraqix.com Patient Portal, a new informative addition to the existing site.
The new Patient Portal section introduces dental patients to Oraqixâ (lidocaine and prilocaine periodontal gel) 2.5%/2.5%, provides a wealth of information on common dental procedures, such as scaling and root planing, and explains the effects that gum disease and periodontitis can have on healthy teeth if left untreated.
Oraqix is the first FDA approved, needle-free dental local anesthetic indicated for use in adults who require localized anesthesia in periodontal pockets during scaling and/or root planing procedures. Oraqix is NOT for injection. Oraqix is administered with a unique OraqixÔ Dispenser. In clinical trials, the most common side effects of Oraqix were application site reaction, headache, and taste perversion. Oraqix is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any other component of the product.
Oraqix is distributed by OraPharma, Inc. Call 1.866.273.7846 for further information or to place an order.